|Last Price$1.29||Day Change (%)-0.77%|
|Open Price$1.30||Day Change ($)-0.01|
|Day Range1.27–1.31||52-Week Range1.26–8.41|
As of Wed 12/24/2014 01:00 PM EST | USD
Exelixis ’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor Conference
Midway Industrial Supply Acquires Contrast Equipment Company
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.